QT Imaging Breast Center Partnership

The Foundation and QT Imaging join Forces for Phase 2 of 3D Breast Imaging Study

Our Foundation and the privately held technology company QT Imaging are in the second phase of a study to map the ducts of the breast. The study, fully funded by the National Institutes of Health, is currently under review by the Institutional Review Board (IRB) and is expected to be approved by the end of summer 2023.

QT’s technology uses a fully automated segmentation, machine learning‐based method to quantitatively assess fibroglandular volumes (FGV), allowing clinicians to determine breast cancer risk and determine response to different treatments.

The research has developed the first 3D printing of the anatomy of the human breast using QT Imaging’s QTscan equipment, which has now received US Food & Drug Administration (FDA) clearance to measure FGV.

The next focus for the partnership is to detect cancerous lesions that a mammogram may miss in women with dense breasts. It is estimated that 47% of women have dense breast tissue, which can make it difficult for radiologists to identify cancer on a mammogram, putting these women at higher risk.

To further the research, the Foundation and QT Imaging have opened up the QT Imaging Breast Center in Beverly Hills, California, for people to come and receive a state-of-the-art breast scan.